NOVN/ROG: Fabulous Fabhalta halts Piasky blue skies

With the recent approval of Roche’s paroxysmal nocturnal haemoglobinuria (PNH) orphan drug C5 inhibitor Piasky, with its unique subcutaneous delivery, as well as Novartis’s alternative Factor B mechanism of action oral Fabhalta potentially changing the treatment paradigm in PAH, we assess the prospects of the various complement inhibitors in PNH and find oral Fabhalta data compelling and see significant hurdles for Roche’s subcutaneous self-administered Piasky